Application of traditional Chinese medicine composition in preparation of medicine for treating and / or preventing renal bone diseases

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for treating and / or preventing renal bone diseases. The traditional Chinese medicine composition comprises pseudo-ginseng, ligusticum wallichii, corydalis tuber, radix paeoniae alba, radix achyranthis bidentatae, rhizoma cibotii, rheum officinale and radix angelicae pubescentis. The traditional Chinese medicine composition can significantly improve the damaged renal function and calcium and phosphorus metabolism; the bone mineral density can be effectively increased; the expression level of BMP-7 protein in bone tissues can be increased, and renal bone diseases can be improved. And the preparation method of the compound combination medicine for treating the renal bone diseases is simple, rapid, efficient and easy to operate. The prepared capsules, tablets, granules, pills, injections and the like are convenient to carry and take.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to the application of a traditional Chinese medicine composition in preparing medicines for treating and / or preventing renal osteodystrophy. Background Art

[0002] Renal osteodystrophy, also known as renal osteodystrophy, is a bone metabolic disorder caused by chronic kidney disease. Its main characteristics are bone lesions, mineral metabolism disorders and vascular calcification, which seriously affect the quality of life of patients.

[0003] The treatment of renal osteodystrophy mainly includes drug therapy, surgical treatment and rehabilitation treatment. In terms of drug therapy, Western medicine plays the role of traditional Chinese medicine. Traditional treatment includes the use of active vitamin D, calcium, phosphorus binders, etc. to regulate calcium and phosphorus metabolism and promote bone health. In recent years, with the in-depth study of the pathogenesis of renal osteodystrophy, new drugs such as calcimimetics and selective vitamin D receptor agonists have gradually been used in clinical practice, providing more options for the treatment of renal osteodystrophy.

[0004] The principle of TCM treatment of renal osteodystrophy is mainly based on the holistic concept and syndrome differentiation of TCM. TCM believes that renal osteodystrophy is related to kidney deficiency, disharmony of qi and blood, and internal blood stasis. Therefore, the basic principles of treatment should be to tonify the kidney and strengthen bones, activate blood circulation and remove blood stasis, and harmonize qi and blood. The active ingredients in TCM can achieve the purpose of treating renal osteodystrophy by regulating kidney function, improving calcium and phosphorus metabolism, and promoting bone repair.

[0005] As a bone metabolic disorder caused by chronic kidney disease, the treatment of renal osteodystrophy is constantly developing and improving. Although the existing treatments can alleviate the patient's condition to a certain extent, there are still many shortcomings. As a unique treatment method, Chinese medicine has shown certain efficacy and advantages in the treatment of renal osteodystrophy. In the future, with the in-depth research of traditional Chinese medicine and the continuous development of modern medical technology, the application of Chinese medicine in the treatment of renal osteodystrophy will be more extensive, and it is expected to bring good news to more patients. At the same time, we also look forward to more research that can deeply explore the pathogenesis and treatment targets of renal osteodystrophy, and provide more effective means for the prevention and treatment of renal osteodystrophy. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide an application of a Chinese medicine composition in the preparation of a drug for treating and / or preventing renal osteodystrophy.

[0007] The invention provides application of a traditional Chinese medicine composition in preparing medicine for preventing and treating renal osteodystrophy.

[0008] The Chinese medicine composition comprises the following raw materials in parts by weight: 100-400 parts of Panax notoginseng, 200-500 parts of Chuanxiong, 200-500 parts of Corydalis, 200-500 parts of White Peony, 200-500 parts of Achyranthes, 100-400 parts of Cibotium barometz, 100-400 parts of Rhubarb and 100-400 parts of Angelica dahurica.

[0009] In some embodiments, the Chinese medicine composition is made of the following raw materials in parts by weight: 335 parts of Panax notoginseng, 445 parts of Chuanxiong, 445 parts of Corydalis yanhusuo, 445 parts of white peony root, 445 parts of Achyranthes bidentata, 335 parts of Cibotium barometz, 335 parts of Rhubarb and 335 parts of Angelica dahurica.

[0010] In the present invention, the preparation method of the Chinese medicine composition as mentioned above comprises:

[0011] (1) Divide Panax notoginseng into two equal parts, one of which is made into coarse powder and the other into fine powder;

[0012] (2) Grind Corydalis yanhusuo, Chuanxiong and Angelica dahurica into coarse powder, combine with coarse powder of Panax notoginseng, and percolate with 4-8 times the amount of 65%-85% ethanol to make a fluid extract;

[0013] (3) Soak white peony root, Achyranthes bidentata, Cibotium barometz and cooked rhubarb in water and boil them 1-2 times, each time for 30-90 minutes. Concentrate the extract to a relative density of 1.15-1.20 at 50°C, add ethanol to make the alcohol content reach 60%-90%, refrigerate for more than 24 hours, filter, recover ethanol from the filtrate and concentrate it to a relative density of 1.15-1.20, add ethanol to make the alcohol content reach 60%-90%, refrigerate for more than 24 hours, filter, recover ethanol from the filtrate and concentrate it;

[0014] (4) Adding the fluid extract of step (2) to the product prepared in step (3), recovering ethanol and concentrating to a thick paste, drying, adding Panax notoginseng fine powder and mixing evenly to prepare a Chinese medicine composition.

[0015] In some embodiments, step (2) of the method for preparing the traditional Chinese medicine composition comprises: grinding Corydalis yanhusuo, Chuanxiong rhizome and Angelica pubescens into coarse powder, combining the powder with Panax notoginseng coarse powder, and percolating with 6 times the amount of 75% ethanol to prepare a fluid extract.

[0016] In some embodiments, step (3) of the method for preparing the Chinese medicine composition comprises: soaking white peony root, Achyranthes bidentata, Cibotium barometz and cooked rhubarb in water and then boiling for 60 minutes, concentrating the extract to a relative density of 1.15-1.20 at 50°C, adding ethanol to make the alcohol content reach 60%, refrigerating for more than 24 hours, filtering, recovering ethanol from the filtrate and concentrating it to a relative density of 1.15-1.20 at 50°C, adding ethanol to make the alcohol content reach 80%, refrigerating for more than 24 hours, filtering, recovering ethanol from the filtrate and concentrating it.

[0017] In some embodiments, the preparation method further comprises: step (5): adding conventional excipients to the traditional Chinese medicine composition of step (4) to prepare a clinically acceptable dosage form.

[0018] Preferably, step (5) of the preparation method is: after crushing the Chinese medicine composition of step (4), adding an appropriate amount of starch, granulating with 10% polyacrylic acid No. 4 resin, and encapsulating.

[0019] In the present invention, the prevention and treatment includes improving renal function, improving calcium and phosphorus metabolism, increasing growth factor levels, improving bone density values ​​and / or improving bone volume fraction.

[0020] There is a close connection between renal function and renal osteodystrophy, and the state of renal function directly affects the health of bone metabolism. The present invention finds that the Chinese medicine composition as described above can improve renal function, thereby playing a role in preventing and treating renal osteodystrophy. In some embodiments, the improvement of renal function includes improving the level of renal function indicators in serum. In some specific embodiments, the improvement of renal function includes reducing urea nitrogen and / or creatinine levels.

[0021] Renal osteodystrophy is a common complication in the progression of chronic kidney disease. Due to decreased kidney function, calcium-phosphorus metabolism imbalance and abnormal bone metabolism occur. In some embodiments, improving calcium-phosphorus metabolism includes: increasing blood calcium levels and reducing blood phosphorus, ALP and iPTH levels.

[0022] The level of BMP-7 is closely related to renal osteodystrophy. BMP-7 plays an important regulatory role in the kidney and bones, and changes in its level may reflect the pathogenesis and progression of renal osteodystrophy. The present invention shows through experiments that the Chinese medicine composition as described above can improve the level of growth factors in bone tissue. In some specific embodiments, the Chinese medicine composition can increase the level of growth factor BMP-7 in bone tissue.

[0023] Bone density and bone volume fraction are important indicators for evaluating renal osteodystrophy. Decreased bone density and reduced bone volume fraction usually indicate the occurrence and development of renal osteodystrophy. In some embodiments, the experiments of the present invention show that the Chinese medicine composition as described above can increase bone density and bone volume fraction.

[0024] Furthermore, the present invention also provides a drug for preventing and treating renal osteodystrophy, which comprises the following raw materials in parts by weight, or is made from the following raw materials in parts by weight:

[0025] 100~400 parts of Panax notoginseng, 200~500 parts of Chuanxiong, 200~500 parts of Corydalis, 200~500 parts of White Peony Root, 200~500 parts of Achyranthes Bidentata, 100~400 parts of Cibotium barometz, 100~400 parts of Rhubarb and 100~400 parts of Angelica dahurica.

[0026] The dosage form of the drug is tablet, capsule, granule, pill, injection, decoction, suspension, dispersant, syrup, suppository, gel, aerosol, patch or oral solution.

[0027] The medicine also includes other active ingredients that can treat and / or improve renal osteodystrophy. The other active ingredients that can treat and / or improve renal osteodystrophy include but are not limited to calcitriol.

[0028] Furthermore, the present invention also provides a method for preventing and treating renal osteodystrophy, which comprises administering the above-mentioned drug. The administration method of the present invention includes but is not limited to oral administration and / or injection.

[0029] The Chinese medicine composition of the present invention comprises Panax notoginseng, Chuanxiong, Corydalis, White Peony, Achyranthes, Cibotium barometz, Rheum officinale and Angelica dahurica. The Chinese medicine composition can significantly improve impaired renal function and calcium-phosphorus metabolism; can effectively increase bone density; can increase the expression level of BMP-7 protein in bone tissue, and improve renal osteodystrophy. Moreover, the preparation method of the compound combination medicine for treating renal osteodystrophy is simple, rapid, efficient and easy to operate. The prepared capsules, tablets, granules, pills, injections and the like are easy to carry and convenient to take. DETAILED DESCRIPTION

[0030] The present invention provides the use of a Chinese medicine composition in the preparation of a drug for treating and / or preventing renal osteodystrophy. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve the above. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0031] The following experiments, if no specific conditions are specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The APIs or excipients, reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially. Unless otherwise specified, all percentages, ratios, proportions or parts are by weight.

[0032] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention. The present invention is further described below in conjunction with the embodiments:

[0033] Example 1 Preparation of Chinese medicine composition

[0034] Panax notoginseng 335g, Ligusticum chuanxiong 445g, Corydalis 445g, White Peony 445g, Achyranthes bidentata 445g, Cibotium barometz 335g, Rhubarb 335g, Angelica dahurica 335g.

[0035] Take half of the above eight ingredients and grind them into fine powder, and store them in another container; grind the other half of the Panax notoginseng into coarse powder. Grind Corydalis, Chuanxiong, and Angelica dahurica into coarse powder, combine them with the coarse powder of Panax notoginseng, and percolate with 6 times the amount of 75% ethanol to make a fluid extract; soak white peony root, Achyranthes bidentata, Cibotium barometz and cooked rhubarb in water and boil for 60 minutes, concentrate the extract to a relative density of 1.15-1.20 at 50°C, add ethanol to make the alcohol content reach 60%, refrigerate for more than 24 hours, filter, recover ethanol from the filtrate and concentrate it to a relative density of 1.15-1.20 at 50°C, add ethanol to make the alcohol content reach 80%, refrigerate for more than 24 hours, filter, recover ethanol from the filtrate and concentrate it to an appropriate volume, add the above fluid extract, recover ethanol and concentrate it to a thick paste, dry, add Panax notoginseng fine powder, mix well, grind, add appropriate amount of starch, granulate with 10% polyacrylic acid No. 4 resin, and encapsulate to make 1000 capsules.

[0036] Experimental Example 2 Therapeutic effect of Chinese medicine composition on renal osteodystrophy model in rats

[0037] 1. Experimental Materials

[0038] 1.1 Animals

[0039] 60 SD rats, male, SPF grade, weighing 180-200 g, were purchased from Hangzhou Medical College (production).

[0040] Breeding environment: room temperature 20~26 ºC, relative humidity controlled at 40~70%, animal breeding density 5 / cage.

[0041] 1.2 Drugs

[0042] The Chinese medicine composition prepared in Example 1 was produced by Jiangsu Kangyuan Pharmaceutical Co., Ltd.; calcitriol capsules (Shanghai Roche Pharmaceuticals Co., Ltd., batch number: B4210); sodium pentobarbital (Beijing Chemical Reagent Company, batch number: 211122); and physiological saline (Chenxin Pharmaceutical Co., Ltd., batch number: 2101282721).

[0043] 1.3 Instruments

[0044] micro-CT scanner (SCANCO, model: vivaCT 80); electronic balance (Sartorius Scientific Instruments, model: BSA224S-CW); purified water instrument (Millipore, Germany, model: Milli-Q Plus); animal weight scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: CX-SC-DA); automatic biochemical analyzer (Thermo Fisher Scientific, USA, model: EL340i).

[0045] 2. Dosage design

[0046] The daily dosage of the Chinese medicine composition is 166g of crude drug / day. According to the body surface area conversion method, the equivalent dose for rats is 166g / 60kg×6.2=17.15g of crude drug / kg. According to the 1 / 4:1 / 2:1 dosing method, the low dose is 4.29g of crude drug / kg and the medium dose is 8.58g of crude drug. Oral administration, 0.1mL / 10g, once a day.

[0047] The rat equivalent dose of calcitriol is 4.5×10 -2 μg / kg. Intragastric administration, 0.1mL / 10g, once a day.

[0048] 3. Experimental Methods

[0049] SD rats were adaptively fed for 3 days and allowed to eat feed and water freely. They were randomly divided into a normal control group, a model control group, a calcitriol control group, and a high-, medium-, and low-dose group of the Chinese medicine composition according to their body weight, with 10 rats in each group.

[0050] A renal osteodystrophy model was established by using rat 5 / 6 nephrectomy combined with high-phosphorus drinking water: after anesthesia, the abdominal cavity of the rats was opened to expose the left kidney. Except for the normal control group, 5 / 6 kidneys were removed in the other groups, and the abdominal cavity was closed after observation without bleeding. Sterile high-phosphorus drinking water (0.5 g / d NaH2PO4) was given from the second day after surgery. One week later, the abdominal cavity was opened again, the right renal artery and the right ureter were clamped and ligated, the right kidney was removed and the abdominal cavity was closed. High-phosphorus drinking water was continued until the end of the experiment. One month after modeling, each dose group was gavaged with the corresponding test solution 0.1mL / 10g. The normal control group and the model control group were gavaged with an equal volume of normal saline, and the positive control group was gavaged with calcitriol 4.5×10 -2 μg / kg, low, medium and high doses of Chinese medicine combination (4.29g / kg, 8.58g / kg, 17.15g / kg), once a day, for 60 consecutive days.

[0051] At the end of the experiment, the rats were anesthetized and blood was collected from the abdominal aorta. After the rats were killed, the left femur was dissected under sterile conditions.

[0052] Detection indicators:

[0053] Serum renal function indexes and calcium-phosphorus metabolism indexes of rats;

[0054] Bone mineral density values ​​and bone volume fraction in rat femur.

[0055] 4. Statistical methods

[0056] The results were statistically analyzed using t-test.

[0057] 5. Experimental Results

[0058] 5.1 Effects on serum renal function indexes and calcium-phosphorus metabolism indexes in rat renal osteodystrophy model

[0059] Compared with the normal control group, the serum levels of BUN, Cr, and blood P in the model group were significantly higher than those in the control group. 3- , ALP, iPTH increased significantly, blood Ca 2 + Compared with the model group, the BUN, Scr, and blood P in the calcitriol group and the high-dose Chinese medicine combination group were significantly reduced. 3- , ALP, iPTH levels were significantly reduced, blood Ca 2+ The results are shown in Table 1 and Table 2.

[0060] Table 1 Effects on serum renal function index levels in rats with renal osteodystrophy ( ± S)

[0061]

[0062] Note: Compared with the normal group, ####P<0.0001; compared with the model group, *P<0.05.

[0063] Table 2 Effects on serum calcium and phosphorus metabolism indexes in rats with renal osteodystrophy ( ± S)

[0064]

[0065] Note: Compared with the normal group, ###P<0.001, ####P<0.0001; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0066] 5.2 Effects on femoral bone mineral density and bone volume fraction in rat renal osteodystrophy model

[0067] Compared with the normal control group, the femoral bone density and bone volume fraction of the model group rats were significantly reduced, indicating that the model was successfully established. Compared with the model group, the bone density and bone volume fraction of the calcitriol group and the high-dose Chinese medicine composition group were significantly increased. This shows that the Chinese medicine composition has a good therapeutic effect on renal osteodystrophy in rats. The results are shown in Table 3.

[0068] Table 3 Effects on femoral bone mineral density and bone volume fraction in rat renal osteodystrophy model ( ± S)

[0069]

[0070] Note: Compared with the normal group, ###P<0.001; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0071] 6. Experimental conclusion

[0072] The Chinese herbal composition (17.15 g crude drug / kg) can significantly regulate serum renal function, calcium-phosphorus metabolism indexes, bone density and bone volume fraction in rat renal osteodystrophy model, indicating that the Chinese herbal composition has a certain therapeutic effect on rat renal osteodystrophy.

[0073] Experimental Example 3 Therapeutic effect of Chinese medicine composition on renal osteodystrophy model in mice

[0074] 1. Experimental Materials

[0075] 1.1 Animals

[0076] C57BL / 6J mice, female, SPF grade, 60 mice, weighing 18-20 g, were purchased from Spectro (Suzhou) Biotechnology Co., Ltd.

[0077] Breeding environment: room temperature 20~26℃, relative humidity controlled at 40~70%, and breeding density of 5 per cage.

[0078] 1.2 Drugs

[0079] The Chinese medicine composition was prepared according to the method of Example 1 and provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.; MouseBMP-7 ELISA Kit (Invitrogen, batch number 310125-003); calcitriol capsules (Shanghai Roche Pharmaceuticals Co., Ltd., batch number: B4210); sodium pentobarbital (Beijing Chemical Reagent Company, batch number: 211122); and normal saline (Chenxin Pharmaceutical Co., Ltd., batch number 2101282721).

[0080] 1.3 Instruments

[0081] micro-CT scanner (SCANCO, model: vivaCT 80); electronic balance (Sartorius Scientific Instruments, model: BSA224S-CW); purified water instrument (Millipore, Germany, model: Milli-Q Plus); animal weight scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: CX-SC-DA); microplate reader (MD Company, USA, model: SpectraMaxM2).

[0082] 2. Dosage design

[0083] The daily dosage of the Chinese medicine composition is 166g of crude drug / day. According to the body surface area conversion method, the equivalent dose for mice is 166g / 60kg×12.3=34.03g of crude drug / kg. According to the 1 / 4:1 / 2:1 dosing method, the low dose is 8.50g of crude drug / kg and the medium dose is 17.01g of crude drug. Oral administration, 0.2mL / 10g, once a day.

[0084] The rat equivalent dose of calcitriol is 8.9*10-2 μg / kg. Oral administration: 0.2mL / 10g, once a day.

[0085] 3. Experimental Methods

[0086] BALB / c mice were adaptively fed for 3 days with free access to feed and water, and were randomly divided into normal control group, model control group, calcitriol control group, high-, medium-, and low-dose groups of the Chinese medicine composition according to body weight, with 10 mice in each group. Except for the normal control group, all animals underwent 5 / 6 nephrectomy. Sterile high-phosphorus drinking water (0.02 g / d NaH2PO4) was given from the second day after surgery until the end of the experiment. One month after modeling, each dose group was gavaged with 0.2 mL / 10 g of the corresponding test solution. The normal control group and the model control group were gavaged with an equal volume of normal saline, and the positive control group was gavaged with calcitriol 8.9×10 -2 μg / kg, low, medium and high doses of the Chinese medicine composition (8.50g / kg, 17.01g / kg, 34.03g / kg), once a day, for 40 consecutive days. After the administration, the mice were killed and the thoracic vertebrae tissues of the mice were obtained.

[0087] Detection indicators:

[0088] Bone mineral density and bone volume fraction of the mouse thoracic spine;

[0089] Expression level of BMP-7 in mouse bone tissue.

[0090] 4. Statistical methods

[0091] The results were statistically analyzed using t-test.

[0092] 5. Experimental Results

[0093] 5.1 Effects on thoracic vertebrae bone mineral density and bone volume fraction in the mouse renal osteodystrophy model

[0094] Compared with the normal control group, the bone density and bone volume fraction of the thoracic vertebrae of the mice in the model group were significantly reduced, indicating that the model was successfully established. Compared with the model group, the bone density and bone volume fraction of the calcitriol group, the high-dose and medium-dose groups of the Chinese medicine composition were significantly increased. This shows that the Chinese medicine composition has a good therapeutic effect on renal osteodystrophy in mice. The results are shown in Table 4.

[0095] Table 4 Effects on thoracic vertebrae bone mineral density and bone volume fraction in the mouse renal osteodystrophy model ( ± S)

[0096]

[0097] Note: Compared with the normal group, ###P<0.001, ####P<0.0001; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0098] 5.2 Effects on the expression level of BMP-7 in bone tissue of mouse renal osteodystrophy model

[0099] The expression level of BMP-7 in the bone tissue of mice was detected by ELISA kit, and the results are shown in Table 5. Compared with the normal control group, the expression level of BMP-7 in the bone tissue of the model group mice was significantly reduced, indicating that the model was successfully established. Compared with the model group, the expression level of BMP-7 in the bone tissue of the calcitriol group, the high-dose and medium-dose groups of the Chinese medicine composition was significantly increased. This shows that the Chinese medicine composition has a good therapeutic effect on renal osteodystrophy in mice.

[0100] Table 5 Effects on the expression level of BMP-7 in bone tissue of mouse renal osteodystrophy model ( ± S)

[0101] Note: Compared with the normal control group, ####P<0.0001; compared with the model control group, ***P<0.001, **P<0.01.

[0102] 6. Experimental conclusion

[0103] The Chinese medicine composition at 34.03 and 17.01 g crude drug / kg can significantly regulate the bone density value, bone volume fraction and BMP-7 expression level in bone tissue of the mouse renal osteodystrophy model, indicating that the Chinese medicine composition has a certain therapeutic effect on mouse renal osteodystrophy.

[0104] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of a Chinese medicine composition in the preparation of a drug for preventing and treating renal osteodystrophy; The Chinese medicine composition comprises the following raw materials in parts by weight: 100-400 parts of Panax notoginseng, 200-500 parts of Chuanxiong, 200-500 parts of Corydalis, 200-500 parts of White Peony, 200-500 parts of Achyranthes, 100-400 parts of Cibotium barometz, 100-400 parts of Rhubarb and 100-400 parts of Angelica dahurica.

2. The use according to claim 1, characterized in that: The Chinese medicine composition is prepared from the following raw materials in parts by weight: 335 parts of Panax notoginseng, 445 parts of Chuanxiong, 445 parts of Corydalis yanhusuo, 445 parts of white peony root, 445 parts of Achyranthes bidentata, 335 parts of Cibotium barometz, 335 parts of Rheum officinale and 335 parts of Angelica dahurica.

3. The use according to claim 1 or 2, characterized in that: The preparation method of the Chinese medicine composition comprises: (1) Divide Panax notoginseng into two equal parts, one of which is made into coarse powder and the other into fine powder; (2) Grind Corydalis yanhusuo, Chuanxiong and Angelica dahurica into coarse powder, combine with coarse powder of Panax notoginseng, and percolate with 4-8 times the amount of 65%-85% ethanol to make a fluid extract; (3) Soak white peony root, Achyranthes bidentata, Cibotium barometz and Rhubarb in water and boil for 1-2 times, each time for 30-90 minutes. Concentrate the extract to a relative density of 1.15-1.20 at 50°C, add ethanol to make the alcohol content reach 60%-90%, refrigerate for more than 24 hours, filter, recover ethanol from the filtrate and concentrate it to a relative density of 1.15-1.20, add ethanol to make the alcohol content reach 60%-90%, refrigerate for more than 24 hours, filter, recover ethanol from the filtrate and concentrate it; (4) Adding the fluid extract of step (2) to the product prepared in step (3), recovering ethanol and concentrating to a thick paste, drying, adding Panax notoginseng fine powder and mixing evenly to prepare a Chinese medicine composition.

4. The use according to claim 3, characterized in that: Step (2) comprises: grinding Corydalis yanhusuo, Chuanxiong and Angelica pubescens into coarse powder, combining the powder with Panax notoginseng coarse powder, and percolating with 6 times the amount of 75% ethanol to prepare a fluid extract; Step (3) comprises: soaking white peony root, Achyranthes bidentata, Cibotium barometz and Rhubarb in water and then boiling for 60 minutes, concentrating the extract to a relative density of 1.15-1.20 at 50°C, adding ethanol to make the alcohol content reach 60%, refrigerating for more than 24 hours, filtering, recovering ethanol from the filtrate and concentrating it to a relative density of 1.15-1.20 at 50°C, adding ethanol to make the alcohol content reach 80%, refrigerating for more than 24 hours, filtering, recovering ethanol from the filtrate and concentrating it.

5. The use according to any one of claims 1 to 4, characterized in that: The prevention and treatment include improving renal function, improving calcium and phosphorus metabolism, increasing growth factor levels, improving bone density values ​​and / or improving bone volume fraction.

6. The use according to claim 5, characterized in that: The improved renal function includes reducing urea nitrogen and / or creatinine levels.

7. The use according to claim 5, characterized in that: The improvement of calcium-phosphorus metabolism includes: increasing blood calcium level, and reducing blood phosphorus, ALP and iPTH levels.

8. The use according to claim 5, characterized in that: The growth factor is BMP-7.

9. A drug for preventing and treating renal osteodystrophy, characterized in that: The invention comprises the following raw materials in parts by weight, or is made from the following raw materials in parts by weight: 100~400 parts of Panax notoginseng, 200~500 parts of Chuanxiong, 200~500 parts of Corydalis, 200~500 parts of White Peony Root, 200~500 parts of Achyranthes Bidentata, 100~400 parts of Cibotium barometz, 100~400 parts of Rhubarb and 100~400 parts of Angelica dahurica.

10. The drug according to claim 9, characterized in that Other active ingredients having the function of treating and / or improving renal osteodystrophy are also included.

Images